

## **Cyclomics Secures New Investment to Accelerate Commercialization of Ultra-Sensitive Cancer Diagnostics by Fast and High-Resolution DNA Sequencing Strategies**

UTRECHT, The Netherlands

7th January 2025

Cyclomics BV, a pioneer in liquid biopsy technology, announces the successful closing of a new investment round led by Myosotis Investments and supported by Oncode Bridge Fund. This capital infusion marks a pivotal transition for the company as it expands its commercial operations to bring innovative diagnostic products to cancer patients.

Cyclomics has developed CyclomicsSeq™, a breakthrough consensus sequencing technology based on intramolecular circularization of circulating tumor DNA (ctDNA) to generate DNA concatemers enabling the detection of ultra-rare mutations in ctDNA at single-molecule resolution. The technology has already been validated through hundreds of clinical samples in partnership with world-class medical centers, like University Medical Center Utrecht, Netherlands Cancer Institute and Princess Maxima Center.

The new funding will drive expansion of the team to get IVDR marked products ready for use in clinical centers and to integrate specialized sales and commercial expertise. Furthermore, Cyclomics will diversify its product portfolio, by advancing Epinn™, a software platform for cancer classification based on DNA methylation patterns. Epinn™ leverages sparse methylation data and state-of-the-art machine learning models (e.g. [Sturgeon](#)) to enable rapid and accurate identification of brain tumors and other cancers.

Following the closing, Cyclomics will strategically relocate its headquarters and laboratories to the Matrix ONE building at Amsterdam Science Park, providing the infrastructure necessary for its next phase of growth.

"With the support of Myosotis Investments and Oncode Bridge Fund, we will accelerate our product development and build a team capable of driving sales to make global impact in cancer diagnostics," said Wigard Kloosterman, Founder and CEO of Cyclomics BV.

Prof. dr. ir. Jeroen de Ridder, co-founder of Cyclomics, Oncode Investigator and Professor in Bioinformatics in Molecular Medicine at the UMC Utrecht and University Utrecht: "Early intervention relies on rapid and superior diagnostic capability. We have validated our technology in clinical environments, achieving rapid diagnosis from tumor biopsies and exceptional sensitivity through non-invasive blood analysis. This is a crucial step forward for improving patient outcomes."

Wietse Mulder, PhD, Managing Director of Myosotis BV, added: "I have observed Cyclomics evolving into a powerhouse of innovation. I am happy to support them with my expertise in commercialization, such to transform Cyclomics and her multidisciplinary team into an

independent provider of innovative diagnostic tools, ultimately enhancing better care of patients suffering from cancer."

Shobhit Dhawan, PhD, Managing Director of Oncode Bridge Fund, noted: "From the outset, we supported Cyclomics, drawn by the rigor of its science and the strength of its entrepreneurial team. The development of the CyclomicsSeq™ and Epinn™ platforms, together with the collaboration with Oxford Nanopore Technologies, demonstrates the company's strong translational potential and focus on delivering meaningful solutions for cancer patients. This latest financing marks a key step in expanding Cyclomics' impact in oncology."

The board of Cyclomics will be made up of executives Wigard Kloosterman and Alessio Marcozzi and non-executive Janeska de Jonge from Myosotis Investments. Wietse Mulder will join the Cyclomics team as part-time consultant on Business Development.

#### **About Cyclomics B.V.**

Founded in 2018 as a spin-off from University Medical Center (UMC) Utrecht, Cyclomics specializes in the intersection of bioinformatics, genomics, and machine learning. The company was founded by Prof. Dr. Ir. Jeroen de Ridder, Dr. Wigard Kloosterman, and Dr. Alessio Marcozzi after winning the Health Holland Venture Challenge. The company has been backed by funding from Oncode Bridge Fund and private investors and has collaborated with Oxford Nanopore Technologies through a long-term collaboration and licensing agreement.

#### **About Myosotis Investments B.V.**

Myosotis Investments was founded in 2024 by dr. Wietse Mulder and is based in Zeist, The Netherlands. The company supports organizations that have a mission-driven approach aiming to impact healthcare leading to better care of patients. The company focuses on advancements in molecular diagnostics and life sciences. Their current portfolio includes innovative firms such as IDEVAX BV, Kairos Biotech Ltd , and Tzu Cancer Therapeutics BV.

#### **About Oncode Bridge Fund**

The Oncode Oncology Bridge Fund is an early-stage life sciences investment fund with a strong focus on oncology, backing mission-driven teams translating excellent science into meaningful patient impact. The fund provides long-term capital and active support to help build enduring companies.

#### **Media contact**

Wigard Kloosterman, CEO ([wigard@cyclomics.com](mailto:wigard@cyclomics.com))

Phone: +31 6 41 22 68 75

[www.cyclomics.com](http://www.cyclomics.com)

Cyclomics B.V.  
Matrix ONE building  
Science Park 301  
1098XH Amsterdam